US/Germany: Bayer said to propose higher Monsanto offer & double the antitrust break fee to $3 billion
Bayer AG is proposing an increased offer and break fee as it tries to clinch the acquisition of Monsanto to create the world’s biggest maker of seeds and pesticides, according to people familiar with the matter.
Bayer is willing to raise its offer to about $129 a share, or $56.5 billion, from $127.50 a share, and double the antitrust break fee to about $3 billion, said the people, who asked not to be identified because the deliberations are private.
Monsanto’s management board is scheduled to discuss and potentially approve the proposal Tuesday, the people said. Bayer’s supervisory board is set to review the deal Wednesday, and an announcement could come shortly thereafter, the people said.
Bayer’s wooing of Monsanto has played out against a backdrop of a rapidly consolidating crop and seed industry, with a series of big deals threatening to leave just a few global players. China National Chemical Corp. agreed in February to acquire Syngenta AG, while DuPont Co. and Dow Chemical Co. plan to merge and then carve out a new crop-science unit.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas